Last reviewed · How we verify
Galactopyranose (GALACTOSE)
Galactose works by interacting with cellular receptors and enzymes to influence various biological pathways.
Galactose is a naturally occurring sugar molecule that serves as a galactose, a small molecule modality. Its mechanism of action is not well established, and it is not FDA approved for any indications. As a naturally occurring compound, galactose is not patented and is likely available from generic manufacturers. However, its commercial status and safety profile are not well documented. Further research is needed to understand its potential therapeutic applications and safety considerations.
At a glance
| Generic name | GALACTOSE |
|---|---|
| Drug class | galactose |
| Target | Jacalin |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | discontinued |
Mechanism of action
Imagine your cells are like a factory, and galactose is a special messenger that helps regulate the flow of materials and energy within the factory. By interacting with receptors and enzymes, galactose can influence how the factory operates, potentially leading to changes in cellular behavior and function. This can have various effects on the body, depending on the specific pathways involved.
Approved indications
Common side effects
Key clinical trials
- Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801) (PHASE2)
- AVTX-801 D-galactose Supplementation in SLC35A2-CDG (PHASE2)
- Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy (PHASE2)
- Dietary Treatment Strategies and Metabolic Control in Glycogen Storage Disease Type I (NA)
- The Effect of Galactooligosaccharides (GOS) on the Gut Microbiota of Lactose Intolerance Individuals (NA)
- Effect of Lactose on Blood Lipids (NA)
- TB006 for Autism Spectrum Disorder (PHASE2)
- GM1 Prophylaxis for WBRT Related Cognitive Dysfunction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |